First AD

Second AD

Lung Cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

CAR T-cell Therapy

 CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment. 

Corey J. Langer, MD

OncLive News Network®

LUX-Lung 8: Afatinib Survival Benefit in Squamous NSCLC

Looking Ahead to the Next Game-Changer in Lung Cancer

CAR T-Cell Therapy in Lung Cancer

Immunotherapy: Potential for Higher Cure Rates in Lung Cancer

Applying Immunotherapy Learnings in Melanoma to Lung Cancer

Checkpoint Inhibition Squamous Cell and Nonsquamous Cell NSCLC

Activity of Afatinib in Lung Cancer

Benefits of Liquid Biopsies in Lung Cancer

EGFR-Resistant Disease in Lung Cancer

Role of Gefitinib in EGRF-Mutant NSCLC

Changing Treatment Landscape in Advanced Lung Cancer